These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

930 related articles for article (PubMed ID: 28049484)

  • 21. Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.
    Li K; Lan Y; Wang J; Liu L
    Tumour Biol; 2017 Mar; 39(3):1010428317692229. PubMed ID: 28347250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.
    Kim MG; Kim D; Suh SK; Park Z; Choi MJ; Oh YK
    Arch Pharm Res; 2016 Apr; 39(4):437-452. PubMed ID: 26895243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chimeric antigen receptor T cell therapy: 25years in the making.
    Gill S; Maus MV; Porter DL
    Blood Rev; 2016 May; 30(3):157-67. PubMed ID: 26574053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unleash the power of the mighty T cells-basis of adoptive cellular therapy.
    Sukari A; Abdallah N; Nagasaka M
    Crit Rev Oncol Hematol; 2019 Apr; 136():1-12. PubMed ID: 30878123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategies to overcome the side effects of chimeric antigen receptor T cell therapy.
    Mirzaee Godarzee M; Mahmud Hussen B; Razmara E; Hakak-Zargar B; Mohajerani F; Dabiri H; Fatih Rasul M; Ghazimoradi MH; Babashah S; Sadeghizadeh M
    Ann N Y Acad Sci; 2022 Apr; 1510(1):18-35. PubMed ID: 34982476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New development in CAR-T cell therapy.
    Wang Z; Wu Z; Liu Y; Han W
    J Hematol Oncol; 2017 Feb; 10(1):53. PubMed ID: 28222796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Establishing guidelines for CAR-T cells: challenges and considerations.
    Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
    Thistlethwaite FC; Gilham DE; Guest RD; Rothwell DG; Pillai M; Burt DJ; Byatte AJ; Kirillova N; Valle JW; Sharma SK; Chester KA; Westwood NB; Halford SER; Nabarro S; Wan S; Austin E; Hawkins RE
    Cancer Immunol Immunother; 2017 Nov; 66(11):1425-1436. PubMed ID: 28660319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increasing the safety and efficacy of chimeric antigen receptor T cell therapy.
    Li H; Zhao Y
    Protein Cell; 2017 Aug; 8(8):573-589. PubMed ID: 28434147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
    Darowski D; Kobold S; Jost C; Klein C
    MAbs; 2019; 11(4):621-631. PubMed ID: 30892136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.
    Cohen AD
    Am Soc Clin Oncol Educ Book; 2018 May; 38():e6-e15. PubMed ID: 30231373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.
    Henderson MA; Yong CS; Duong CP; Davenport AJ; John LB; Devaud C; Neeson P; Westwood JA; Darcy PK; Kershaw MH
    Immunotherapy; 2013 Jun; 5(6):577-90. PubMed ID: 23725282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Next generation engineered T cells for cell therapy: from lymphoma to solid tumors].
    Catros V
    Med Sci (Paris); 2019 Apr; 35(4):316-326. PubMed ID: 31038109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Promise of Chimeric Antigen Receptor T-Cell Therapy.
    Frey NV; Porter DL
    Oncology (Williston Park); 2016 Oct; 30(10):880-8, 890. PubMed ID: 27744645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conjugated CAR T cell one step beyond conventional CAR T cell for a promising cancer immunotherapy.
    Hallaj S; Meshkini F; Chaleshtari MG; Ghorbani A; Namdar A; Soleimanpour H; Jadidi-Niaragh F
    Cell Immunol; 2019 Nov; 345():103963. PubMed ID: 31445668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CAR-T cell therapy in melanoma: A future success story?
    Simon B; Uslu U
    Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.